<DOC>
	<DOCNO>NCT00003832</DOCNO>
	<brief_summary>Phase II trial study effectiveness broxuridine treat patient undergo surgery stage I stage II prostate cancer . Broxuridine may help doctor determine rate growth prostate tumor help plan effective treatment</brief_summary>
	<brief_title>Broxuridine Plus Surgery Treating Patients With Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Measure potential doubling time multifocal adenocarcinoma prostate use broxuridine . II . Determine whether double time multifocal carcinoma occur within single prostate consistent model low-volume carcinoma slow double time high-volume carcinoma fast double time . OUTLINE : Patients receive broxuridine IV 30 minute day -1 . Approximately 12-96 hour later , patient undergo surgery remove prostate . Tumor tissue examine immunostaining presence broxuridine determine double time tumor .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bromodeoxyuridine</mesh_term>
	<criteria>Diagnosis stage I II ( T12 ) carcinoma prostate PSA great 8 ng/mL Abnormal finding digital rectal examination Eligible radical prostatectomy Performance status ECOG 0 1 No prior biologic therapy No prior chemotherapy No prior neoadjuvant hormonal therapy No prior radiotherapy See Disease Characteristics No prior therapy would affect tumor growth rate volume</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>